



an Open Access Journal by MDPI

10th Anniversary of Biomedicines—Induced Pluripotent Stem Cells: 15 Years after the Discovery

Guest Editor:

Dr. M. Esther Gallardo

Head of Translational Research
with iPS Cells Group, Research
Institute Hospital 12 de Octubre,
i+12, Madrid, Spain

Deadline for manuscript
submissions:

closed (30 November 2023)

Message from the Guest Editor

Dear Colleagues,

It is our great pleasure to announce the 10th anniversary of the journal *Biomedicines*. To celebrate this anniversary, we are launching a Special Issue entitled “10th Anniversary of *Biomedicines*—Induced pluripotent stem cells: 15 years after the discovery”. Since the creation of induced pluripotent stem cells (iPSCs), by the Nobel Prize laureate Dr. Shinya Yamanaka, many laboratories worldwide are working to generate and apply these cells to the investigation of the ethiopathogeny behind diseases and the search for new therapies against them. The aim of this Special Issue is to collect high-quality papers, fully dedicated to iPSCs and their applications, from top experts in this field. In particular, we encourage researchers to present comprehensive review papers and original articles that highlight the most recent advances in this topic.

- induced pluripotent stem cells
- organoids
- tissue engineering
- biomaterials
- reprogramming
- iPSC-based cell modelling
- cell therapy
- microfluidics
- drug discovery



mdpi.com/si/107853

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI